Clinical outcome of Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly in the rituximab era.
Bottom Line: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of malignant lymphoma.The incidence of Epstein-Barr virus (EBV)-positive DLBCL in Asian and Latin American countries ranges from 8 to 10%.The outcome of patients with EBV-positive DLBCL remains poor, even in the rituximab era.
Affiliation: Department of Hematology-Oncology, School of Medicine, Tokai University, Isehara, Japan.Show MeSH
Related in: MedlinePlus
Mentions: The median follow-up time of surviving patients was 25.2 months (range, 0.8–71.3 months). Median OS was 8.7 months in EBV-positive patients and was not reached in EBV-negative patients (P < 0.0001; Fig.1). Three EBV-positive patients could not receive chemotherapy because their general condition was poor and disease progression was rapid.
Affiliation: Department of Hematology-Oncology, School of Medicine, Tokai University, Isehara, Japan.